Citations

Clear

4610 citation(s) found for "Lu, Brian".

Primary Care Physician Use of Elastic Scattering Spectroscopy on Skin Lesions Suggestive of Skin Cancer
Merry, Stephen , Croghan, Ivana T. , Dukes, Kimberly A. , McCormick, Brian C. , Considine, Gerard T. , Duvall, Michelle J., Thompson, Curtis , Leffell, David J. , Merry, Stephen P , Thompson, Curtis T

Mayo Clinic

Journal of Primary Care & Community Health | June 5, 2025 | Volume: 16 | Issue: No issue available | Pages: No page available

10.1177/21501319251344423 | PMID 40470593 Get It

Objectives: To evaluate the performance of noninvasive, elastic scattering spectroscopy, algorithm-powered device (DermaSensor) to detect melanoma and basal and squamous cell cancers in the primary care setting. Patients & Methods: DERM-SUCCESS, a blinded, prospective, multicenter pivotal study, enrolled adult patients between August 17, 2020, and December 9, 2021, with lesions that their primary care physicians (PCPs) suspected of skin cancer at clinics in the US (n = 18) and Australia (n = 4). These lesions were assessed by PCPs and scanned with the DermaSensor device. Biopsy specimens were collected, and histopathologic analysis was performed by dermatopathologists. The diagnostic performance of the device, dermatopathologist discordance, and subgroup analyses of clinical interest were calculated. Results: Of the 1579 skin lesions enrolled, dermatopathologic analysis identified 224 (14.2%) cancers. Device sensitivity was 95.5% (95% CI, 91.7%-97.6%) overall and 96.3% (92.9%-98.4%) for patients in the FDA-approved age group 40 years and older (90.2% for melanoma, 97.8% for basal cell carcinoma, and 97.7% for squamous cell carcinoma). Device specificity was 20.7%. The negative predictive value was 96.6%, and the positive predictive value was 16.6% (NNB 6). The device misclassified as “ monitor ” rather than “ investigate further ” 4 keratinocyte carcinomas and 4 melanomas in patients aged 40 years or older (n = 8, 0.5% of lesions, 3.7% of cancers biopsied). Conclusions: The DermaSensor device is an easy-to-use, point-of-care, hand-held skin cancer adjunctive diagnostic device with high sensitivity and NPV to help inform PCP decision-making about skin lesions suspicious for cancer that need further evaluation and those that may be monitored.
Risk factors, impact, and healthcare use related to initial suicide attempts: comprehensive analysis of Swedish population
Hu, Kejia , Dung, Nguyen Thi Thuy , Borges, Karen, Kuja‐Halkola, Ralf , Butwicka, Agnieszka , Brikell, Isabell , Crowley, James J, D’Onofrio, Brian M. , Larsson, Henrik , Lu, Yi , Crowley, James J. , Nguyen, Thuy-Dung , Rück, Christian , Hu, Kejia , Kuja-Halkola, Ralf , Lu, Yi , Brikell, Isabell , Crowley, James J, Chang, Zheng, Lichtenstein, Paul , Bulik, Cynthia Marie , Sullivan, Patrick F. , Fang, Fang , Crowley, James J.

Mayo Clinic

BMJ Medicine | June 5, 2025 | Volume: 4 | Issue: 1 | Pages: e001129

10.1136/bmjmed-2024-001129 | PMID 40510927 Get It

Objective To provide a comprehensive analysis of initial suicide attempts, covering incidence, risk factors, outcomes, and healthcare use in the month before and the month after the attempts. Design Comprehensive analysis of the Swedish population that included three designs: a retrospective cohort study to investigate incidence and healthcare use, a nested case-control study to investigate risk factors, and a matched cohort study to examine subsequent suicide attempts and mortality. Setting Comprehensive Swedish national registers that include patient diagnoses from hospitals and specialist outpatient care, and cause of death information updated to the end of 2019. Participants 3.7 million people born in Sweden in 1963-98 and followed from age 10 to 57 years. Main outcome measure First lifetime suicide attempt identified in patient and death registers using ICD (international classification of diseases) codes for intentional self-harm, any self-harm with lethal methods or requiring hospital admission, or any self-harm resulting in death. Results The lifetime risk of an initial suicide attempt in the study population was 4.6%, with greater risk in females and highest risk between ages 18 and 24. One in 10 families in Sweden had at least one family member who attempted suicide. Overdose and poisoning were the most common methods. Previous psychiatric disorders, general medical diseases, and adverse life events were associated with increased risk of initial suicide attempt, while higher socioeconomic status was associated with decreased risk. People with an initial suicide attempt were at substantially increased risk of subsequent attempts (hazard ratio 23.4), death by suicide (16.4), and all cause mortality (7.3). At least 60% of those who made an initial suicide attempt had a healthcare contact in the month before the attempt. Conclusions This study provides comprehensive data on the incidence, risk factors, outcomes, and healthcare use of initial suicide attempts in the Swedish population, highlighting the need for systematic prevention efforts for people who have attempted suicide for the first time.
Bronchoscopic lung volume reduction: model for assisted target lobe selection
Hostetter, Logan , Brown, Leah M, Rajagopalan, Srinivasan , Dulohery-Scrodin, Megan, Edell, Eric S. , Lester, Michael , Maldonado, Fabien , Lentz, Robert J. , Bartholmai, Brian J. , Peikert, Tobias, Dulohery-Scrodin, Megan M, Bartholmai, Brian J , Brown, Leah M

Mayo Clinic

BMJ Open Respiratory Research | June 5, 2025 | Volume: 12 | Issue: 1 | Pages: e002903

10.1136/bmjresp-2024-002903 | PMID 40473270 Get It

Introduction Bronchoscopic lung volume reduction with endobronchial valves (EBV) is an effective procedure for patient with severe emphysema to improve lung function, exercise tolerance, dyspnoea and quality of life. Optimisation of patient and treatment lobe selection is essential for successful EBV outcomes. While clinical selection criteria are rigorous, many centres use a multidisciplinary team and rely on previous clinical experience for the selection process. To aid objective clinical decision making, we present a mathematical model to facilitate patient and target lobe selection. Methods A multidisciplinary team reviewed quantitative high-resolution computed tomography (HRCT) analysis from 119 patients to select candidates for EBV and to select a treatment lobe. Two logistic regression models, (1) candidacy for EBV placement and (2) target-lobe selection, were developed based on the normalised distributions of the four quantitative HRCT variables (fissure completeness score, per cent of voxel density with HU < −910 and HU < −950, and lobar volumes) across all five lung lobes. An external cohort of 50 patients (25 candidates and 25 non-candidates) was used to validate the prediction model. Results Performance measures of the training cohort demonstrated an area under the curve (AUC) of 0.91, accuracy of 81%, sensitivity of 93% and specificity of 78% compared with the multidisciplinary teams’ target lobe selection. The validation cohort demonstrated an AUC of 0.89, accuracy of 84%, sensitivity of 88% and specificity of 83% compared with the multidisciplinary team decision making. Conclusions Endobronchial valve lung volume reduction remains a potent palliative measure to improve quality of life in patients with hyperinflated emphysema. Our model for target lobe selection harnesses the multidisciplinary experience at a tertiary care centre to objectively select candidates and target lobes to assist clinicians’ decision making. Future studies investigating prediction of lobar collapse and functional improvement after target lobe selection using our model are needed.
Association between empirical dietary inflammatory pattern (EDIP) and survival in patients with stage III colon cancer: Findings from CALGB/SWOG 80702 (Alliance).
Char, Sara K., Kumthekar, Priya , Guthrie, Katherine A. , Couture, Félix , Kuebler, J. Phillip, Kumar, Pankaj , Tan, Benjamin , Krishnamurthi, Smitha , Wolpin, Brian M. , Geoffroy, Francois J., Shields, Anthony F. , Ng, Kimmie , Char, Sara K., Shi, Qian , Zemla, Tyler , Ma, Chao , Cheng, En , Tabung, Fred K. , O’Reilly, Eileen M. , Meyerhardt, Jeffrey A. , Yuan, Chen

Mayo Clinic

Journal of Clinical Oncology | June 4, 2025 | Volume: 43 | Issue: 17_suppl | Pages: No page available

10.1200/jco.2025.43.17_suppl.lba3509 Get It

LBA3509 Background: Systemic inflammation has been implicated in colon cancer progression. We examined whether intake of a proinflammatory diet is associated with survival among patients (pts) with stage III colon cancer. Methods: This prospective cohort study was nested within a randomized phase III trial of adjuvant therapy in pts with stage III colon cancer who had undergone curative-intent resection. EDIP score – a validated tool to classify the inflammatory nature of diets – was derived as a cumulative exposure using data from food-frequency questionnaires completed within 6 weeks of randomization and 14-16 months (mo) after randomization. Cox proportional hazards regression was used to assess the associations of EDIP with disease-free survival (DFS) and overall survival (OS). Results: Of 1625 included pts, the mean (SD) age was 60.9 (10.5) years (yrs). Compared to pts in the lowest EDIP quintile, pts in the highest quintile (a more inflammatory diet) were younger (58.7 ± 10.8 vs 61.3 ± 9.5 yrs old) and more likely to be female (64.0% vs 48.9%) and have worse performance status (ECOG 1-2: 35.7% vs 19.4%). Pts in the highest quintile were less likely to be White (76.6% vs 92.0 %) and more likely to be Black (15.4% vs 3.7%). Baseline aspirin use, assigned chemotherapy (3 mo vs 6 mo), and assigned pharmacotherapy (celecoxib vs placebo) were not significantly different across EDIP quintiles. Compared with pts in the lowest EDIP quintile, pts in the highest quintile had significantly worse OS (multivariable hazard ratio [HR] 1.87, 95% confidence interval [CI] 1.26-2.77, P trend =0.01), but not DFS (HR 1.36, 95% CI 0.99-1.86, P trend =0.22). Diet and physical activity jointly influenced OS. Those with lower EDIP scores (quintiles 1-4, 80% of the study population) and higher physical activity (≥9 MET-h/wk) had the best OS (HR 0.37, 95% CI 0.25-0.53) compared with pts in the highest EDIP quintile (20% of the study population) and lower physical activity (<9 MET-h/wk) ( P interaction <0.001). The association between higher EDIP and OS was consistent when analyzed by celecoxib and placebo treatment arms ( P interaction 0.54). The relationship between EDIP and OS did not differ significantly according to aspirin use, with HR 1.60 (95% CI 0.71-3.60) among aspirin users and HR 2.01 (95% CI 1.27-3.16) among aspirin non-users ( P interaction 0.06). Conclusions: Our findings suggest that greater intake of a proinflammatory dietary pattern is associated with worse OS in pts with stage III colon cancer. Regular physical activity may attenuate the association, and further investigation of diet and physical activity intervention is warranted. Support: U10CA180821, U10CA180882, U24CA196171, U10CA180863, CCS 707213, UG1CA233234, U10CA180820, U10CA180868, U10CA180888; https://acknowledgments.alliancefound.org. Pfizer; ClinicalTrials.gov Identifier: NCT01150045.
Hyperinsulinemia-induced upregulation of adipocyte TPH2 contributes to peripheral serotonin production, metabolic dysfunction, and obesity
Park, Brian I., Reeves, Andrew R., Wilson, Robin A. , Fernandes, Sophia C., Buhman, Kimberly K. , Lytle, Kelli A. , Jensen, Michael D. , Greenberg, Andrew S. , Park, Brian I., Reeves, Andrew R., Zhu, Ying , Fernandes, Sophia C., Jensen, Michael

Mayo Clinic

Journal of Clinical Investigation | June 4, 2025 | Volume: 135 | Issue: 14 | Pages: No page available

10.1172/jci190765 | PMID 40455408 Get It

Tryptophan hydroxylase (TPH) is a rate-limiting enzyme for serotonin or 5-hydroxytryptamine (5-HT) synthesis. Previously, adipocyte TPH1 has been linked to increased adipose 5-HT, reduced brown adipose tissue (BAT) thermogenesis, and obesity. However, the role of TPH2, a neural isoform highly expressed in obese adipose tissue, is unknown. Here, we report that adipose tissue expression of TPH2 is dramatically elevated in mice with diet-induced obesity (DIO) and ob/ob mice, as well as in obese humans. In mice fed a high-fat diet, adipocyte TPH2 deficiency improved DIO-induced metabolic complications, enhanced BAT thermogenesis, and increased intestinal energy-harvesting efficiency without affecting adiposity. Conversely, TPH2 overexpression in epididymal adipocytes of chow-fed mice raised adipose and plasma 5-HT levels, suppressed BAT thermogenesis, and exacerbated obesity and metabolic dysfunction. We found that obesity-induced hyperinsulinemia upregulated adipocyte TPH2 expression via activation of mechanistic target of rapamycin complex 1 and SREBP1. In humans, TPH2 mRNA levels in subcutaneous adipose tissue, but not those of TPH1 , are positively correlated with fasting plasma insulin concentrations. In summary, our study demonstrates that obesity-associated increases in adipocyte TPH2 can regulate distal tissue physiology and energy metabolism, suggesting that TPH2 could be a potential therapeutic target for obesity and its associated complications.
Antithrombotic Treatment for Stroke Prevention in Cervical Artery Dissection: The STOP-CAD Study
Yaghi, Shadi, Shu, Liqi , Mandel, Daniel , Henninger, Nils , Muppa, Jayachandra , Affan, Muhammad , Lodhi, Omair ul haq , Heldner, Mirjam R. , Seiffge, David , Omran, Setareh Salehi , Crandall, Ross , Lester, Evan, Mena, Diego López, Araúz, Antonio , Nehme, Ahmad , Boulanger, Marion , Sousa, João André , Sargento‐Freitas, João , Barata, Vasco , Castro‐Chaves, Paulo , Brito, Maria Teresa , Khan, Muhib , Mallick, Dania, Rothstein, Aaron , Khazaal, Ossama , Kaufmann, Josefin E. , Engelter, Stefan T. , Traenka, Christopher , Sousa, Diana Aguiar de , Soares, Mafalda , Rosa, Sara , Zhou, Lily , Gandhi, Preet , Field, Thalia S. , Mancini, Steven, Metanis, Issa , Pan, Kelly , Dantu, Vishnu , Baumgartner, Karl , Nolte, Christian H. , Choi, Richard , MacDonald, Jason , Shahripour, Reza Bavarsad , Ghannam, Malik , Almajali, Mohammad , Sanchez, Sebastian , Zine-Eddine, Fayçal, Poppe, Alexandre Y. , Fonseca, Ana Catarina , Baptista, Maria Fortuna , Cruz, Diana , Marco, Giovanna De , Griffin, Kim, Kuohn, Lindsey , Frontera, Jennifer , Amar, Jordan , Giles, James , Grisendi, Ilaria , Nzwalo, Hipólito , Liebeskind, David S. , Molaie, Amir , Cavalier, Annie, Kam, Wayneho , Grory, Brian Mac , Kasab, Sami Al , Eltatawy, Ali , Chervak, Lina , Chulluncuy‐Rivas, Roberto, Aziz, Yasmin , Bakradze, Ekaterina , Tran, Thanh Lam , Rodrigo‐Gisbert, Marc , Velez, Faddi Saleh, Gracia, Jorge Ortiz, Mudassani, Varsha, Vishnu, Venugopalan Y. , Yaddanapudi, Sridhara , Adams, L, Browngoehl, Abigail, Ranasinghe, Tamra , Dunston, Randy, Lynch, Zachary, Penckofer, Mary , Mayer, Silvia, Zubair, Adeel , Cheng, Yee Kuang, Ferreira, Vítor Mendes , Asad, Syed Daniyal , Sarwat, Zoha, Balabhadra, Anvesh , Patel, Shivam , Secchi, Thaís , Mantovani, Gabriel, Kim, Young Dae , Krishnaiah, Balaji , Elangovan, Cheran , Lingam, Sivani, Quereshi, Abid, Alvarado, Alonso, Khasiyev, Farid , Linares, Guillermo , Mannino, Marina , Terruso, Valeria, Vassilopoulou, Sofia , Tentolouris, Vasilis, Martínez-Marino, Manuel , Wall, Victor Carrasco , Indraswari, Fransisca , Jamal, Sleiman El , Alvi, Muhammad , Sarvath, Mohammed, Kass‐Hout, Tareq , Shi, Feina , Zhang, Jinhua , Said, Jamil , Sen, Shayak, Ghani, Mohammad R , Elnazeir, Marwa , Xiao, Han , Kala, Narendra , Khan, Farhan , Mohammadzadeh, Nahid , Furie, Karen L. , Alvarado‐Bolaños, Alonso , Tentolouris-Piperas, Vasileios , Leon Guerrero, Christopher R , Henninger, Nils , Muppa, Jayachandra , Heldner, Mirjam R , Liebeskind, David S. , Field, Thalia S , Keser, Zafer , Aziz, Yasmin , Mandel, Daniel M , Seiffge, David , Arauz, Antonio , Sousa, Joao Andre , Sargento-Freitas, Joao , Castro-Chaves, Paulo , Kaufman, Josefin E , Engelter, Stefan T , Aguiar de Sousa, Diana , Soares, Mafalda , Rosa, Sara , Metanis, Issa , Nolte, Christian H , Bavarsad Shahripour, Reza , Almajali, Mohammad , Fonseca, Ana Catarina , Kuohn, Lindsey , Frontera, Jennifer , Giles, James , Nzwalo, Hipolito , Mac Grory, Brian , Eltatawy, Ali , Rodrigo Gisbert, Marc , Vishnu, Venugopalan Y , Ranasinghe, Tamra , Mendes Ferreira, Vítor , Kim, Young Dae , Elangovan, Cheran , Alvarado-Bolanos, Alonso , Khasiyev, Farid , Tentolouris-Piperas, Vasileios , Martinez Marino, Manuel , Ghani, Mohammad , Xiao, Han , Khan, Farhan , Nehme, Ahmad , Yaghi, Shadi , Antonenko, Kateryna , Arnold, Marcel , Touzé, Emmanuel , Leker, Ronen R , Burton, Tina , von Rennenberg, Regina , MacDonald, Jason, Guo, Xiaofan , Samaniego, Edgar A , Rioux, Bastien , Cruz, Diana , Romoli, Michele , Longoni, Marco , Keser, Zafer , Zedde, Marialuisa , Pascarella, Rosario , Anadani, Mohammad , Kicielinski, Kimberly , Requena, Manuel , Velez, Faddi G. Saleh , Havenon, Adam de , Siegler, James E. , Willey, Joshua , Sharma, Richa , Marto, João Pedro , Klein, Piers , Nguyen, Thanh N. , Martins, Sheila , Fridman, Sebastian , Liu, Shilin , Ali, Farman, Morsi, Rami Z. , Sokhi, Dilraj , Simpkins, Alexis N. , Gomez, Roberto, Sen, Shayak, Stretz, Christoph , Goldstein, Eric

Mayo Clinic

Stroke | June 4, 2025 | Volume: 55 | Issue: 4 | Pages: 908-918

10.1161/strokeaha.123.045731 | PMID 38335240 Get It

BACKGROUND: Small, randomized trials of patients with cervical artery dissection showed conflicting results regarding optimal stroke prevention strategies. We aimed to compare outcomes in patients with cervical artery dissection treated with antiplatelets versus anticoagulation. METHODS: This is a multicenter observational retrospective international study (16 countries, 63 sites) that included patients with cervical artery dissection without major trauma. The exposure was antithrombotic treatment type (anticoagulation versus antiplatelets), and outcomes were subsequent ischemic stroke and major hemorrhage (intracranial or extracranial hemorrhage). We used adjusted Cox regression with inverse probability of treatment weighting to determine associations between anticoagulation and study outcomes within 30 and 180 days. The main analysis used an as-treated crossover approach and only included outcomes occurring with the above treatments. RESULTS: The study included 3636 patients (402 [11.1%] received exclusively anticoagulation and 2453 [67.5%] received exclusively antiplatelets). By day 180, there were 162 new ischemic strokes (4.4%) and 28 major hemorrhages (0.8%); 87.0% of ischemic strokes occurred by day 30. In adjusted Cox regression with inverse probability of treatment weighting, compared with antiplatelet therapy, anticoagulation was associated with a nonsignificantly lower risk of subsequent ischemic stroke by day 30 (adjusted hazard ratio [HR], 0.71 [95% CI, 0.45–1.12]; P =0.145) and by day 180 (adjusted HR, 0.80 [95% CI, 0.28–2.24]; P =0.670). Anticoagulation therapy was not associated with a higher risk of major hemorrhage by day 30 (adjusted HR, 1.39 [95% CI, 0.35–5.45]; P =0.637) but was by day 180 (adjusted HR, 5.56 [95% CI, 1.53–20.13]; P =0.009). In interaction analyses, patients with occlusive dissection had significantly lower ischemic stroke risk with anticoagulation (adjusted HR, 0.40 [95% CI, 0.18–0.88]; P interaction =0.009). CONCLUSIONS: Our study does not rule out the benefit of anticoagulation in reducing ischemic stroke risk, particularly in patients with occlusive dissection. If anticoagulation is chosen, it seems reasonable to switch to antiplatelet therapy before 180 days to lower the risk of major bleeding. Large prospective studies are needed to validate our findings.
Patterns of Care Following Procedural Intervention Among Women With Overactive Bladder
Jefferson, Francis A. , Khan, Aqsa , Gebhart, John B. , Elliott, Daniel S. , Linder, Brian J. , Hanson, Kristine T. , Khan, Aqsa A, Linder, Brian J

Mayo Clinic

Neurourology and Urodynamics | June 4, 2025 | Volume: 44 | Issue: 6 | Pages: 1332-1338

10.1002/nau.70088 | PMID 40462581 Get It

ABSTRACTIntroduction and ObjectiveProcedural therapies for overactive bladder (OAB) most often include intradetrusor onabotulinumtoxinA (BTX) injections, sacral neuromodulation (SNM), and percutaneous tibial nerve stimulation (PTNS). Despite their proven efficacy, real‐world data on therapy continuation and crossover rates between these modalities remain limited. This study aimed to evaluate longitudinal patterns of treatment continuation and therapy crossover among women receiving procedural OAB treatments.MethodsWe conducted a multi‐institutional retrospective cohort study of women with idiopathic OAB who underwent index BTX, SNM, or PTNS between 2014 and 2022. Patients were identified using electronic medical records, and follow‐up data were collected through December 31, 2023. The primary outcomes included duration of maintenance treatments and crossover to another procedural therapy for OAB. Kaplan–Meier survival analysis estimated rates of continued treatment, and a log‐rank test assessed differences in crossover rates among treatment groups.ResultsA total of 506 women met inclusion criteria: 266 (52.6%) received BTX, 114 (22.5%) underwent SNM, and 126 (24.9%) received PTNS. Ongoing treatment rates were lowest for PTNS, with only 17.1% maintaining therapy between 3 and 5 years and 26.1% crossing over to another procedure within 3 years. Among BTX patients, 65.2% underwent repeat treatment within 3 years, and 9.5% of patients crossed over to another procedure within 3 years. Of those with 5 or more years of follow‐up, 39.1% of patients continued with BTX procedures in the 3–5‐year follow‐up timeframe. Among SNM patients, the cumulative revision rates were 7.6% at 1 year and 10.9% at 2 years. 13.1% of patients crossed over from SNM to another procedure within 3 years (the vast majority to BTX).ConclusionsPTNS had the lowest ongoing therapy rates and the highest crossover rates. BTX and SNM demonstrated similar crossover rates. These findings underscore the importance of individualized patient counseling and treatment selection based on expectations of therapy persistence. Future research should focus on optimizing patient selection, improving long‐term adherence strategies, and evaluating novel or combined therapeutic approaches for OAB management.
Outcomes of a Virtual Medicine Hybrid Model for Postoperative Care Following Mastectomy and Immediate Tissue Expander Breast Reconstruction
Paton, Madeline M. , TerKonda, Sarvam P. , Ho, Olivia A. , Rinker, Brian, Forte, Antonio J. , Maniaci, Michael J.

Mayo Clinic

Annals of Plastic Surgery | June 3, 2025 | Volume: 94 | Issue: 6S | Pages: S562-S563

10.1097/sap.0000000000004392 | PMID 40459460 Get It

Introduction The Care Hotel is a virtual medicine hybrid model of care implemented at the Mayo Clinic to increase use of enhanced recovery protocols, address hospital capacity and reduce medical costs. This voluntary accommodation offers patients a comfortable environment to receive nursing care postoperatively with in-person daytime monitoring and 24-hour virtual telemonitoring in a hotel setting. This study aims to evaluate postoperative outcomes in patients admitted to the Care Hotel after mastectomy with immediate tissue expander reconstruction compared to standard overnight admission. Methods A retrospective review of the electronic medical record was conducted for patients who underwent mastectomy with immediate tissue expander reconstruction prior to (1/2019–1/2020) and after (7/2021–7/2023) the implementation of the Care Hotel. Postoperative outcomes, including 48-hour ED visit, 48-hour readmission, and 30-day infection, hematoma, seroma, admission, and return to operating room were collected. Results There were 61 patients with 108 tissue expander reconstructions in the hospital admission group and 122 patients with 212 tissue expander reconstructions in the Care Hotel group. The average length of hospital stay was 1.2 days while the average Care Hotel stay was 1.4 days. There were four 48-hour ED visits with 1 admission for 12 hours of observation in the Care Hotel group. There was no statistically significant difference in 30-day infection, seroma, hematoma, readmission, need for IR drain procedure or return to operating room between the groups. Conclusions This investigation demonstrates the safety of postoperative virtual telemonitoring and should encourage providers to utilize virtual visit technology in the immediate postoperative time-period.
The Impact of a Novel Transfer Process on Patient Bed Days and Length of Stay: A Five-Year Comparative Study at the Mayo Clinic in Rochester and Mankato Quaternary and Tertiary Care Centers
Khedr, Anwar , Hassan, Esraa, Asim, Rida , Khan, Muhammad Khuzzaim , Duseja, Nikhil , Attallah, Noura , Mueller, J. I. , Newman, James S. , Loomis, Erica, Bartelt, Jennifer M., Khan, Syed Anjum , Bartlett, Brian , Mueller, Jennifer , Newman, Jamie , Bartelt, Jennifer, Khedr, Anwar , Khan, Syed Anjum , Bartlett, Brian

Mayo Clinic

International Journal of Environmental Research and Public Health | June 3, 2025 | Volume: 22 | Issue: 6 | Pages: 871

10.3390/ijerph22060871 | PMID 40566300 Get It

Introduction: This study evaluated the impact of parallel-level patient transfers on bed utilization efficiency within the Mayo Clinic Health System in Southern Minnesota, focusing on optimizing resources across tertiary and critical access hospitals. Methods: A retrospective analysis of 179,066 Emergency Department visits (2018–2022) was conducted, with ~2% involving parallel-level transfers for observation or admission. Machine learning was utilized to identify patients suitable for parallel transfers based on demographics, comorbidities, and clinical factors. A Random Forest model with an AUROC of 0.87 guided transfer decisions. Saved patient days were calculated as the difference between the actual LOS and the benchmark LOS based on Diagnosis-Related Groups (DRGs). Generalized estimating equations analyzed length of stay (LOS) differences, adjusted for confounders, with 95% confidence intervals (CI). Statistical analyses were conducted using SPSS (v.26). Results: The mean patient age was 56 years (SD = 17.2), with 51.4% being female. Saved patient days increased from ~600 to 5200 days over the study period. Transferred patients had a 5.7% longer unadjusted LOS compared to non-transferred patients (95% CI: 2.9–8.6%, p < 0.001). After adjustment for demographics and comorbidities, the LOS difference was not significant (adjusted mean difference: 0.4%, 95% CI: −1.7–2.5%, p = 0.51). Conclusions: Parallel-level transfers increased saved patient days, reflecting enhanced resource utilization. However, the adjusted LOS differences were not significant, highlighting the need for robust transfer protocols and controlled studies to confirm these findings.
Low Dose Rapamycin Alleviates Clinical Symptoms of Fatigue and PEM in ME/CFS Patients via Improvement of Autophagy
Ruan, Brian T., Bulbule, Sarojini , Reyes, Amy, Chheda, Bela, Bateman, Lucinda , Bell, Jennifer , Yellman, Braydon, Berner, Jon , Peterson, Daniel L., Kaufman, David L. , Gottschalk, C. Gunnar , Grach, Stephanie, Roy, Avik , Ruan, Brian T. , Gile, Brooke, Reyes, Amy, Bell, Jennifer, Yellman, Brayden P., Grach, Stephanie L.

Mayo Clinic

No container title available | June 3, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6596158/v1 | PMID 40502741 Get It

Abstract Background: mTOR activation is associated with chronic inflammation in ME/CFS. Previous studies have shown that sustained mTOR activation can cause chronic muscle fatigue by inhibiting ATG13-mediated autophagy. This highlights the pivotal role of mTOR in the pathogenesis of ME/CFS. Methods: We conducted a decentralized, uncontrolled trial of rapamycin in 86 patients with ME/CFS to evaluate its safety and efficacy. Low-dose rapamycin (6 mg/week) was administered, and core ME/CFS symptoms were assessed on days 30 (T1), 60 (T2), and 90 (T3). Plasma levels of autophagy metabolites, such as pSer258-ATG13 and BECLIN-1, were measured and correlated with clinical outcomes, specifically MFI. Results: Rapamycin (6 mg/week) was tolerated without any SAEs. Of the 40 patients, 29 (72.5%) showed strong recovery in PEM, fatigue, and OI, along with improvements in MFI fatigue domains and SF-36 aspects. High levels of BECLIN-1 were detected in T3. Plasma pSer258-ATG13 levels were strongly downregulated at T1. Spearman’s correlation analysis indicated an association between autophagy impairment and reduced activity. Conclusions: Low-dose rapamycin effectively reduced PEM and other key symptoms in patients with ME/CFS, as measured by BAS, SSS, MFI, and SF-36. Future studies should encompass dose optimization and develop a diagnostic tool to identify responders with mTOR-mediated autophagy disruption.